Rezolute, Inc. (RZLT) stock
RZLTNasdaqPharmaceutical PreparationsFiscal year ends June 30
$4.01+0.43 (+12.15%)
Close on Nov 17, 2026Market cap $388.34MP/E –Yield –
Rezolute ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Rezolute's ebitda for the twelve months ending Sep 30, 2026 was -$82.50M. For fiscal 2026 it was -$82.94M. The highest annual figure on record is -$5.16M in fiscal 2014.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -$82.94M | – |
| FY2025 | Jun 30, 2025 | -$79.86M | – |
| FY2024 | Jun 30, 2024 | -$70.39M | – |
| FY2023 | Jun 30, 2023 | -$55.96M | – |
| FY2022 | Jun 30, 2022 | -$41.83M | – |
| FY2021 | Jun 30, 2021 | -$22.88M | – |
| FY2020 | Jun 30, 2020 | -$20.50M | – |
| FY2019 | Jun 30, 2019 | -$25.90M | – |
| FY2018 | Jun 30, 2018 | -$27.67M | – |
| FY2014 | Jun 30, 2014 | -$5.16M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Sep 30, 2026 | -$19.38M | – |
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | -$21.55M | – |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | -$17.36M | – |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | -$24.21M | – |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | -$19.81M | – |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | -$25.84M | – |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | -$20.02M | – |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | -$17.07M | – |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | -$16.93M | – |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | -$23.10M | – |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | -$16.20M | – |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | -$15.18M | – |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -$15.90M | – |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | -$14.23M | – |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | -$17.13M | – |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | -$14.39M | – |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | -$10.22M | – |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | -$11.30M | – |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -$10.75M | – |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | -$12.15M | – |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | -$7.64M | – |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | -$6.63M | – |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -$5.48M | – |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -$7.15M | – |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | -$3.62M | – |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | -$3.55M | – |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | -$5.07M | – |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | -$6.72M | – |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | -$5.17M | – |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | -$11.05M | – |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | -$4.69M | – |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | -$5.48M | – |
See a number that looks wrong?